

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



泰 達

天津泰達生物醫學工程股份有限公司

Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8189)

Grant of Award Shares under the Share Award Scheme

This announcement is made under Rules 23.06A, 23.06B and 23.06C of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”).

Reference is made to the circular (the “**Circular**”) and the notice of the extraordinary general meeting (the “**EGM**”) dated 12 August 2025 and the announcement of the poll results of the EGM dated 29 August 2025 of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) in relation to, among other things, the resolutions for the Shareholders’ consideration and approval of the proposed adoption of the Share Award Scheme (the “**Award Scheme**”), the proposed Service Provider Sublimit and the proposed authorization to be granted to the Board. Unless the context otherwise requires, the terms used herein shall have the same meanings as those defined in the Circular.

The Board hereby announces that the Company has granted an aggregate of 4,000,000 Award Shares to a Grantee under the Award Scheme on 21 October 2026, subject to acceptance by the Grantee.

Particulars of the Award Shares Granted

The particulars of the Award Shares granted to the Grantees are as follows:

Grant Date:	21 October 2026
Grantee:	A total of one (1) Eligible Participant, named Ms. Li Wanchen, who is the director of a subsidiary of the Company, Shenzhen Yishu Jingcheng Technology Co., Ltd. (深圳醫數精誠科技有限公司) and holds 49% of the shareholding of this company.
Number of Award Shares Granted:	4,000,000 Award Shares, corresponding to 4,000,000 H Shares.
Purchase Price of the Award Shares:	The Grantee is not required to pay any purchase price for the Award Shares.
Close Price of the H Shares at the Grant Date:	HK\$0.175 per H Share
Vesting Period:	The Award Shares shall vest upon the expiry of 12 months from the Grant Date in one tranche.
Performance Targets and Clawback Mechanism:	The vesting of the Award Shares granted are not subject to any performance targets or any clawback mechanism. Given that Ms. Li Wanchen has made significant contributions to the undertaking, design and construction of the Group's "One Cloud, One Lake, One Platform" municipal high-standard public data operation platform project in Yinchuan, which has established a benchmark case for the Group in the field of public data operation, the Remuneration Committee is of the view that the grant of Award Shares, without performance targets and/or a clawback mechanism, aligns with the purpose of the Share Award Scheme.

The 4,000,000 awarded H Shares represent the value of approximately HK\$700,000 calculated based on the closing price of the H Shares on the date of the grant of HK\$0.175 per H Share.

The grant of Award Shares to the above Grantee has been approved by the independent non-executive Directors pursuant to Rule 23.04(1) of the GEM Listing Rules, the Remuneration Committee and the Board. The grant of the Award Shares to the Grantee would not result in the Shares issued and to be issued in respect of all awards granted to the Grantee (excluding any awards lapsed in accordance with the terms of the applicable scheme) in the 12-month period up to and including the Grant Date representing in aggregate over 0.1% of the issued Shares (excluding treasury Shares). As such, the grant of the Award Shares to the Grantee would not be subject to approval by the Shareholders pursuant to Rule 23.04(4) of the GEM Listing Rules.

Reasons for and Benefits of the Grant of Award Shares

The Board considers the grant of Award Shares an effective means to reward and motivate the Grantee to contribute to the Group's long-term value creation. This initiative encourages the Grantee to help the Group meet critical milestones, achieve key strategic objectives, and sustain business growth. Aligning the Grantee's interests with the company's trajectory ensures they share in its ongoing success, fulfilling the goals of the Share Award Scheme while safeguarding the interests of the Company and its shareholders.

Implications of the GEM Listing Rules

The Stock Exchange has previously approved the listing and trading of the new Shares which may be issued in respect of Award Shares that may be granted under the Share Award Scheme.

The Award Shares granted may be settled by the issue of new H Shares and/or transfer of treasury shares under the Award Scheme. Pursuant to the Scheme Mandate Limit, the maximum aggregate number of H Shares to be newly allotted and issued in connection with share awards or share options granted under all share schemes of the Company is 143,640,000 Shares. Immediately following this Grant, the number of Shares available for future grants under the Scheme Mandate Limit is 139,640,000 Shares.

Pursuant to the Service Provider Sublimit, the maximum aggregate number of H Shares to be newly allotted and issued to service providers in connection with share awards or share options

granted under all share schemes of the Company is 43,092,000 Shares. Immediately following this Grant, the number of Shares available for future grants to service providers under the Service Provider Sublimit is 43,092,000 Shares.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
21 October 2026

As at the date of this announcement, the executive directors of the Company are Ms. Sun Li and Mr. Yang Zeng; the non-executive directors of the Company are Mr. He Xin, Dr. Li Ximing, Mr. Wang Lei and Mr. Xia Alan Zhe; the independent non-executive directors of the Company are Ms. Gao Chun, Mr. Tu Xiangzhen and Mr. Chen Jiang.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the Stock Exchange's website at <http://www.hkexnews.hk> on the "Latest Listed Company Information" page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.